Reckitt Benckiser Pharmaceuticals Inc. has entered into a definitive agreement with AntiOp, Inc, a specialty pharmaceutical company based in Lexington Kentucky, pharmaceutical company, to co-develop a naloxone nasal spray to aid in the reversal of opioid overdose with the option to acquire all rights to the product upon receipt of regulatory and marketing approval. The product has the potential to be the first of its kind to treat overdose from opioid prescription painkillers and heroin

Currently, the standard medical protocol for treating opioid overdose is to administer an injectable form of naloxone. It must be administered intravenously or as a shot into muscle or under the skin. The product is a nasal alternative using AntiOp’s drug nasal formulation that uses a prefilled, unit-dose, disposable delivery system designed for insertion into the nose of an overdose victim to administer naloxone across the nasal mucosal membrane for absorption.

Source: Reckitt Benckiser Pharmaceuticals